Limited suppression of prostate-specific antigen after salvage radiotherapy for its isolated elevation after radical prostatectomy

Urology

Volumn 53, Issue 1, 1999, Pages 148-154

  Egawa, Shin ^a   Matsumoto, Kazumasa ^a   Suyama, Kazuho ^a   Soh, Shigehiro ^a   Kuwao, Sadahito ^a   Iwamura, Masatsugu ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SALVAGE THERAPY; TREATMENT OUTCOME;

AGED; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SALVAGE THERAPY;

EID: 0032928365     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00442-7     Document Type: Article

References (21)

1. Stamey T.A., Yang N., Hay A.R., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 317:1987;909-916.
2. Dillioglugil O., Miles B.J., Scardino P.T. Current controversies in the management of localized prostate cancer. Eur Urol. 28:1995;85-101.
3. Paulson D.F. Impact of radical prostatectomy in the management of clinically localized disease. J Urol. 152:1994;1826-1830.
4. Witherspoon L.R., Lapeyrolerie T. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy. J Urol. 157:1997;1322-1328.
5. Takayama T.K., Krieger J.N., True L.D., et al. Recurrent prostate cancer despite undetectable prostate specific antigen. J Urol. 148:1992;1541-1542.
6. Urological tumours. Sobin L.H., Wittekind C.H. TNM Classification of Malignant Tumours. 5th ed. 1997;170-173 John Wiley & Sons, New York.
7. Machida T., Ohishi Y., Wada T., et al. Clinical evaluation of a new kit (IMx PA Dainapack) for detection of serum prostate specific antigen. Acta Urol Japonica. 39:1993;977-984.
8. Arai T., Tsukada T., Nakayama T. Evaluation of AxSYM automated immunoassay analyzer system for determining prostate-specific antigen, and comparison of reactivities for the antigen and diagnostic values of several commercial kits. J Med Pharm Sci. 32:1994;125-136.
9. Egawa S., Koh H., Satoh T., et al. Preoperative serum prostate-specific antigen, clinical stage and Gleason sum as basis for predicting final pathological stage in Japanese prostate cancer. Jpn J Clin Oncol. 26:1996;438-444.
10. Flocks R.H. The treatment of stage C prostate cancer with special reference to combined surgical and radiation therapy. Trans Am Assoc Genitour Surg. 64:1972;58-60.
11. Anscher M.S., Prosnitz L.R. Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule. J Urol. 138:1987;1407-1412.
12. Medini E., Medini I., Reddy P.K., et al. Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up. Cancer. 78:1996;1254-1259.
13. Link P., Freiha F.S., Stamey T.A. Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy. J Urol. 145:1991;532-534.
14. Lange P.H., Lightner D.J., Medini E., et al. The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels. J Urol. 144:1990;927-933.
15. Coetzee L.J., Hars V., Paulson D.F. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology. 47:1996;232-235.
16. Partin A.W., Pound C.R., Clemens J.Q., et al. Serum PSA after anatomic radical prostatectomy. Urol Clin North Am. 20:1993;713-725.
17. Schild S.E., Buskirk S.J., Wong W.W., et al. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol. 156:1996;1725-1729.
18. Cadeddu J.A., Partin A.W., DeWeese T.L., et al. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol. 159:1998;173-178.
19. Partin A.W., Pound C.R., Pearson J.D., et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 43:1994;649-659.
20. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Conformal external beam treatment of prostate cancer. Urology. 50:1997;87-92.
21. Crook J.M., Bahadur Y.A., Robertson S.J., et al. Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. Cancer. 79:1997;81-89.